ReviewJournal of thoracic disease2025
Pulmonary ossification: a review.
Review in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary ossification (PO) is a rare disease, especially in patients without a previous history of lung disease. PO has an indolent course that may progressively cause lung function impairment. It is characterized by the presence of ectopic metaplastic bone in the lungs. Although it is generally idiopathic, it may be associated with other diseases, such as interstitial lung diseases. High resolution computed tomography (HRCT) of the chest is the technology of choice for diagnosis, as it allows differential diagnosis with other diseases and spares the use of more aggressive diagnostic techniques. Distinctive radiological findings include two ossification patterns: dendriform and nodular (the most frequent). Each pattern is associated with specific histological findings and can be related to different entities or otherwise be idiopathic forms. This review provides an updated overview of the pathogenesis, diagnostic and histopathological criteria and prognostic factors. As specific treatment is not currently available, the objective is to prevent fibrotic interstitial progression. For a correct management of the disease, it is necessary to consider the associated comorbidities and closely monitor cases. The purpose of this approach is to prevent progression, in case it is associated with diffuse interstitial lung disease. Further research and long-term follow-up are necessary for a better understanding of the pathogenesis and prognosis of PO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.